Neon therapeutics, inc. (NTGN)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Operating expenses:
Research and development

9,446

12,691

14,120

16,735

16,172

18,022

14,441

14,804

13,158

11,530

7,332

General and administrative

7,220

5,298

5,134

5,580

5,408

5,752

4,612

4,313

3,599

2,612

2,432

Total operating expenses

16,666

17,989

19,254

22,315

21,580

23,774

19,053

19,117

16,757

14,142

9,764

Loss from operations

-16,666

-17,989

-19,254

-22,315

-21,580

-23,774

-19,053

-19,117

-16,757

-14,142

-9,764

Other income (expense), net
Interest income

68

149

278

418

556

655

672

218

247

153

162

Other expense

-

-

4

35

-

5

10

0

10

-

-

Total other income (expense), net

-

-

274

383

-

650

662

218

237

153

162

Net Income (Loss) Attributable to Parent

-16,598

-17,840

-18,980

-21,932

-21,024

-23,124

-18,391

-18,899

-16,520

-13,989

-9,602

Temporary Equity, Accretion to Redemption Value, Adjustment

-

-

0

0

-

0

0

3,185

3,186

2,530

2,503

Net loss attributable to common stockholders

-

-

-18,980

-21,932

-

-23,124

-18,391

-22,084

-19,706

-16,519

-12,105

Net loss per share, basic and diluted (in dollars per share)

-0.58

-0.63

-0.68

-0.79

-0.76

12.44

-0.67

-7.84

-9.47

-9.59

-7.55

Weighted average common shares outstanding, basic and diluted (in shares)

28,535

28,141

27,935

27,787

27,651

27,891

27,357

2,815

2,080

1,722

1,603

Comprehensive loss:
Net Income (Loss) Attributable to Parent

-16,598

-17,840

-18,980

-21,932

-21,024

-23,124

-18,391

-18,899

-16,520

-13,989

-9,602

Other comprehensive income:
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent

0

0

0

8

67

-51

-22

6

5

14

-24

Total other comprehensive income

0

0

0

8

67

-51

-22

6

5

14

-24

Comprehensive loss

-16,598

-17,840

-18,980

-21,924

-20,957

-23,175

-18,413

-18,893

-16,515

-13,975

-9,626